Sumanta Kumar Pal, MD

Articles

Experience Using Cabozantinib And Nivolumab for Advanced RCC

October 15th 2020

Sequencing Therapies for Advanced Renal Cell Carcinoma

October 15th 2020

Impact of CheckMate 9ER on the Treatment of Advanced RCC

October 15th 2020

Data from the CheckMate 9ER Trial for Advanced RCC

October 15th 2020

Treatment Landscape of Advanced Renal Cell Carcinoma

October 15th 2020

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC

October 1st 2020

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

September 15th 2020

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

September 10th 2020

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

June 24th 2020

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Dr. Pal on the Potential Use of PARP Inhibitors in RCC

February 11th 2020

Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.

Dr. Pal on CRISPR-Based Technology in RCC

October 4th 2019

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Dr. Pal on the Design of the SWOG 1500 Trial in Papillary RCC

July 23rd 2019

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).

Dr. Pal on Molecular Signatures in Renal Cell Carcinoma

March 7th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

Dr. Pal on the Clinical Utility of PD-L1 in mRCC

January 12th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).

Dr. Pal on Developments in Frontline Treatments for Patients With mRCC

December 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses developments made in frontline treatment for patients with metastatic renal cell carcinoma (mRCC).

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC

September 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the frontline approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic renal cell carcinoma (RCC).

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC

June 27th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.

Dr. Pal on an Enrolling Clinical Trial for Patients With GU Cancers

June 4th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.

Dr. Pal on the Mutational Burden in Bladder Cancer

December 27th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.